Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.34 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 4/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798685 | 0.80 | CYP26A1 (0.38) | CYP26A1CYP24A1ESR1ESR2 | |
| SCHEMBL6799504 | 0.77 | CYP26A1 (0.44) | CYP26A1CYP24A1ESR1ESR2 | |
| SCHEMBL173365 | 0.66 | PREP (0.49) | PREPESR1ESR2CA12CA1 | |
| SCHEMBL6802039 | 0.63 | CA12 (0.43) | PREPCA12CA1CA9 | |
| SCHEMBL2523819 | 0.63 | CA12 (0.56) | PREPESR1ESR2CA12CA1 | |
| SCHEMBL5379895 | 0.62 | PREP (0.53) | PREPESR1ESR2CA12CA1 | |
| SCHEMBL7286280 | 0.62 | PREP (0.41) | PREPCA12CA1CA9 | |
| SCHEMBL7536765 | 0.62 | ACHE (0.39) | PREPCA12CA1CA9 | |
| SCHEMBL2522567 | 0.61 | CA12 (0.54) | PREPESR1ESR2CA12CA1 | |
| SCHEMBL6796424 | 0.60 | SHBG (0.40) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | CYP26A1 353/4885PREP 3181/4885CYP24A1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.